Raia Drogasil (OTCMKTS:RADLY – Get Free Report) released its earnings results on Tuesday. The company reported $0.05 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.05, Zacks reports.
Raia Drogasil Trading Up 3.3%
Raia Drogasil stock traded up $0.12 on Tuesday, hitting $3.77. The company’s stock had a trading volume of 2,842 shares, compared to its average volume of 54,849. The company has a fifty day moving average price of $3.56 and a 200-day moving average price of $4.23. Raia Drogasil has a one year low of $2.62 and a one year high of $5.34.
Wall Street Analysts Forecast Growth
Separately, Zacks Research raised Raia Drogasil to a “hold” rating in a report on Thursday, April 9th. One analyst has rated the stock with a Hold rating, Based on data from MarketBeat.com, the company currently has an average rating of “Hold”.
Raia Drogasil Company Profile
Raia Drogasil SA is a leading Brazilian retail pharmacy operator, offering a comprehensive range of prescription and over-the-counter medications, health and wellness products, personal care and beauty items, as well as a selection of convenience goods. The company’s network of stores operates under the Raia and Drogasil banners, serving diverse consumer needs across major urban centers. Complementary services include in-store prescription dispensing, compounding pharmacies and health screening programs such as blood pressure and glucose monitoring.
The company was formed in 2011 through the merger of two established Brazilian pharmacy chains, Drogasil and Droga Raia, each with origins dating back several decades.
Featured Stories
- Five stocks we like better than Raia Drogasil
- System Upgrade: First Internet Bancorp Options Surge
- AI Security Breaches Raise New Risks for Microsoft and Amazon’s Agent Push
- The AI Chip Blockade Is Creating a Shadow Market
- Grab Holdings Stock Forms Bottom After Strong Beat-and-Raise Quarter
Receive News & Ratings for Raia Drogasil Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Raia Drogasil and related companies with MarketBeat.com's FREE daily email newsletter.
